Secondary cytoreduction plus oxaliplatin-based HIPEC in platinum-sensitive recurrent ovarian cancer patients: A pilot study

Gynecologic Oncology

Volumn 113, Issue 3, 2009, Pages 335-340

  Fagotti, A ^a   Paris, I ^b   Grimolizzi, F ^a   Fanfani, F ^a   Vizzielli, G ^a   Naldini, A ^a   Scambia, G ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

HIPEC; Ovarian cancer; Oxaliplatin; Recurrence; Secondary cytoreduction

Indexed keywords

DOCETAXEL; OXALIPLATIN; PLATINUM;

ADULT; ARTICLE; ASCITES; CANCER RECURRENCE; CARCINOMATOSIS; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; MULTIPLE CYCLE TREATMENT; OVARY CANCER; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL;

ADULT; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; INFUSIONS, PARENTERAL; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; SURVIVAL ANALYSIS;

EID: 67349248443     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.03.004     Document Type: Article

References (37)

1. McGuire W.P., Hoskins W.J., Brady M.F., Kucera P.R., Partridge E.E., Look K.Y., Clarke-Pearson D.L., and Davidson M. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group). Semin. Oncol. 23 5 Suppl 12 (1996) 40-47
2. Muggia F.M., Braly P.S., Brady M.F., Sutton G., Niemann T.H., Lentz S.L., Alvarez R.D., Kucera P.R., and Small J.M. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study. J. Clin Oncol. 18 (2000) 106-115
3. Ozols R.F., Bundy B.N., Greer B.E., Fowler J.M., Clarke-Pearson D., Burger R.A., Mannel R.S., deGeest K., Hartenbach E.M., Baergen R., and Gynecologic Oncology Group. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J. Clin Oncol. 21 (2003) 3194-3200
4. Alberts D.S., Green S., Hannigan E.V., O'Toole R., Stock-Novack D., Anderson P., Surwit E.A., Malvlya V.K., Nahhas W.A., and Jolles C.J. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J. Clin Oncol. 10 (1992) 706-717 [see comment, erratum appears in J Clin Oncol 1992 Sep;10:1505]
5. Díaz-Montes T.P., and Bristow R.E. Secondary cytoreduction for patients with recurrent ovarian cancer. Curr. Oncol. Rep. 7 6 (2005) 451-458
6. Ferrandina G., Ludovisi M., Lorusso D., Pignata S., Breda E., Savarese A., Del medico P., Scaltriti L., Katsaros D., Priolo D., and Scambia G. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J. Clin Oncol. 26 (2008) 890-896
7. Shiu M.H., and Fortner J.G. Intraperitoneal hyperthermic treatment of implanted peritoneal cancer in rats. Cancer Res. 40 (1980) 4081-4084
8. Vernon C. Hyperthermia in cancer growth regulation. Biotherapy 4 (1992) 307-315
9. Akaboshi M., Tanaka Y., Kawai K., Akuta K., Masunaga S., and Ono K. Effect of hyperthermia on the number of platinum atoms binding to DNA of HeLa cells treated with 195mPt-radiolabelled cis-diaminedichloroplatinum (II). Int. J. Radiat. Biol. 66 (1994) 215-220
10. Fujimoto S., Takahashi M., Mutou T., Kobayashi K., Toyosawa T., and Ohkubo H. Improved mortality rate of gastric carcinoma patients with peritoneal carcinomatosis treated with intraperitoneal hyperthermic chemoperfusion combined with surgery. Cancer 79 (1997) 884-891
11. Loggie B.W., Fleming R.A., McQuellon R.P., Russell G.B., Geisinger K.R., and Levine E.A. Prospective trial for the treatment of malignant peritoneal mesothelioma. Am. Surg. 67 (2001) 999-1003
12. Sugarbaker P.H., and Chang D. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann. Surg. Oncol. 6 (1999) 727-731
13. Witkamp A.J., De Bree E., Kaag M.M., boot H., Beijnen J.H., van Slooten G.W., van Coevorden F., and Zoetmulder F.A. Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin. Eur. J. Cancer 37 (2001) 979-984
14. Deraco M., Rossi C.R., Pennacchioli E., Guadagni S., Somers D.C., santoro N., raspagliesi F., Kusamura S., and Vaglini M. Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion in the treatment of recurrent epithelial ovarian cancer: a phase II clinical study. Tumori 7 (2001) 120-126
15. Panteix G., Beaujard A., Garbit F., Chaduiron-Faye C., Guillamont M., Gilly F., Baltassat P., and Bressolle F. Population pharmacokinetics of cisplatin in patients with advanced ovarian cancer during intraperitoneal hyperthermia chemotherapy. Anticancer Res. 22 (2002) 1329-1336
16. Helm C.W., Martin R.S., Metzinger D.S., and Edwards R.P. Secondary surgical cytoreduction and hyperthermic intraperitoneal chemotherapy for recurrent ovarian and endometrial cancer. Int. Gynecol. Cancer Soc. 14 Suppl 1 (2004) 167
17. Dieras V., Bougnoux P., Petit T., Chollet P., Beuzeboc P., Borel C., Husseini F., Goupil A., Kerbrat P., Misset J.L., Bensmaine M.A., Tabah-Fisch I., and Pouillart P. Multicentre phase II study of oxaliplatin as a single agent in cisplatin/carboplatin +/- taxane-pretreated ovarian cancer patients. Ann. Oncol. 13 2 (2002) 258-266
18. Delaloge S., Laadem A., Taamma A., Chouaki N., Cvitkovic E., Pautier P., Misset J.L., and Lhommè C. Pilot study of the paclitaxel, oxaliplatin, and cisplatin combination in patients with advanced/recurrent ovarian cancer. Am. J. Clin Oncol. 23 6 (2000) 569-574
19. Elias D., Bonnay M., Puizillou J.M., Antoun S., Demirdjian S., El O.A., Pignon J.P., Drouard-troalen L., Ouellet J.F., and Ducreux M. Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann. Oncol. 13 (2002) 267-272
20. Elias D., Pocard M., and Goere D. HIPEC with oxaliplatin in the treatment of peritoneal carcinomatosis of colorectal origin. Cancer Treat res. 134 (2007) 303-318
21. Vasey P.A., Jayson G.C., Gordon A., et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin chemotherapy for ovarian carcinoma. J. Natl. Cancer Inst. 96 22 (2004) 1682-1691
22. Ferrandina G., Ludovisi M., De Vincenzo R., Salutari V., Lorusso D., Colangelo M., Prantera T., Valerio M.R., and Scambia G. Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: a phase II study. Ann. Oncol. 18 (2007) 1348-1353
23. Fagotti A., Fanfani F., Rossitto C., Lorusso D., De gaetano A.M., Giordano A., Vizzielli G., and Scambia G. A treatment selection protocol for recurrent ovarian cancer patients: the role of fdg-pet/ct and staging laparoscopy. Oncology 75 3-4 (2008) 152-158
24. Bijelic L., Jonson A., and Sugarbaker P.H. Systematic review of cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis in primary and recurrent ovarian cancer. Ann. Oncol. 18 (2007) 1943-1950
25. Younan R., Kusamura S., Baratti D., and Cloutier AS e Deraco M. Morbidity, toxicity, and mortality classification systems in the local regional treatment of peritoneal surface malignancy. J. Surg. Oncol. 98 (2008) 253-257
26. National Cancer Institute. Cancer Therapy Evaluation Program: Common Toxicity Criteria. Version 2.0 1999; http://ctep.info.nih.gov (20 April 1999, date last accessed).
27. Rizzo J.D., Lightin A.E., Woolf S.H., et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J. Clin Oncol. 10 (2002) 4083-4107
28. Ferrandina G., Legge F., Salutari V., Paglia A., Testa A., and Scambia G. Impact of pattern of recurrence on clinical outcome of ovarian cancer patients: clinical considerations. Eur. J. Cancer 42 (2006) 2296-2302
29. Rustin G.J., Quinn M., Thigpen T., du Bois A., Pujade-Lauraine E., Jakobsen A., Eisenhauer E., Sagae S., Greven K., Vergote I., Cervantes A., and Vermorken J. New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). Natl. Cancer Inst 96 6 (2004) 487-488
30. Portilla A.G., Shigeki K., Dario B., and Deraco M. The intraoperative staging systems in the management of peritoneal surface malignancy. J. Surg. Oncol. 98 (2008) 228-231
31. Helm C.W., Bristow R.E., Kusamura S., Baratti D., and Deraco M. Hyperthermic intraperitoneal chemotherapy with and without cytoreductive surgery for epithelial ovarian cancer. J. Surg. Oncol. 98 (2008) 283-290
32. Harter P., Du Bois A., Hahmann M., et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann. Surg. Oncol. 13 (2006) 1702-1710
33. Bristow R.E., Puri I., and Chi D.S. Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol. Oncol. 112 (2009) 265-274
34. Rose P.G., Nerenstone S., Brady M.F., et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. N. Engl. J. Med. 351 (2004) 2489-2497
35. Onda T., Yoshikawa H., Yasugi T., Yamada M., Matsumoto K., and Taketani Y. Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: proposal for patients selection. Br. J. Cancer 92 (2005) 1026-1032
36. Ceelen W.P., Peeters M., Houtmeyers P., Breusegem C., De Somer F., and Pattyn P. Safety and efficacy of hyperthermic intraperitoneal chemoperfusion with high-dose oxaliplatin in patients with peritoneal carcinomatosis. Ann. Surg. Oncol. 15 (2008) 535-541
37. Markman M., Markman J., Webster K., Zanotti K., Kulp B., Peterson G., and Belinson J. Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J. Clin Oncol. 22 (2004) 3120-3125